Anemia News and Research

RSS
Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.
Anemia prevention in pregnancy: an interview with Juan Pablo Peña-Rosas, WHO

Anemia prevention in pregnancy: an interview with Juan Pablo Peña-Rosas, WHO

Researchers identify how telomerase is recruited to chromosome ends

Researchers identify how telomerase is recruited to chromosome ends

FibroGen receives FDA Orphan Drug Designation for FG-3019 to treat IPF

FibroGen receives FDA Orphan Drug Designation for FG-3019 to treat IPF

Progress with GSK in advancing VaxiRNA technology earns Alnylam $3.2M milestone payment

Progress with GSK in advancing VaxiRNA technology earns Alnylam $3.2M milestone payment

FDA grants priority review to GSK’s Promacta sNDA for treatment of thrombocytopenia

FDA grants priority review to GSK’s Promacta sNDA for treatment of thrombocytopenia

HemoGlobe device can identify women with anemia

HemoGlobe device can identify women with anemia

Bioniche receives U.S. and Canadian approval for first of two canine oncology products

Bioniche receives U.S. and Canadian approval for first of two canine oncology products

When checks and balances in the pharmaceutical marketplace fall short

When checks and balances in the pharmaceutical marketplace fall short

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

FDA grants accelerated approval for Kyprolis to treat multiple myeloma

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

FDA grants accelerated approval to Onyx's Kyprolis for treatment of multiple myeloma

Statistical method uses evolutionary information to enhance identification of disease-associated alleles

Statistical method uses evolutionary information to enhance identification of disease-associated alleles

Positive preliminary results from Feraheme phase III study on iron deficiency anemia

Positive preliminary results from Feraheme phase III study on iron deficiency anemia

Positive results from Alnylam’s ALN-TTR02 Phase I trial on TTR-mediated amyloidosis

Positive results from Alnylam’s ALN-TTR02 Phase I trial on TTR-mediated amyloidosis

New paper documents discovery of novel lipids, including MC3

New paper documents discovery of novel lipids, including MC3

Two cellular proteins team up to provide steady supply of RBCs

Two cellular proteins team up to provide steady supply of RBCs

NOXXON commences Spiegelmer NOX-A12 Phase IIa trial in CLL

NOXXON commences Spiegelmer NOX-A12 Phase IIa trial in CLL

Thrombopoietin mimetic offers aplastic anemia hope

Thrombopoietin mimetic offers aplastic anemia hope

Anemia prevention in pregnancy works just as well with fewer iron supplements

Anemia prevention in pregnancy works just as well with fewer iron supplements

Research finds new single-gene cause of chronic kidney disease

Research finds new single-gene cause of chronic kidney disease

Jehovah’s Witnesses’ beliefs do not necessarily put them at risk

Jehovah’s Witnesses’ beliefs do not necessarily put them at risk

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.